Carson Wealth (CWM LLC)
ELVN icon

Carson Wealth (CWM LLC)’s Enliven Therapeutics ELVN Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.57K Buy
142
+48
+51% +$1.33K ﹤0.01% 4984
2025
Q4 		$1K Sell
94
-18
-16% -$359 ﹤0.01% 5203
2025
Q3 		$2K Buy
112
+21
+23% +$423 ﹤0.01% 4994
2025
Q2 		$2K Buy
91
+61
+203% +$1.16K ﹤0.01% 4874
2025
Q1 		$1K Buy
30
+16
+114% +$344 ﹤0.01% 4894
2024
Q4 		$0 Buy
14
+2
+17% +$52 ﹤0.01% 4968
2024
Q3 		$0 Buy
12
+5
+71% +$116 ﹤0.01% 4900
2024
Q2 		$0 Buy
7
+3
+75% +$63 ﹤0.01% 4670
2024
Q1 		$0 Buy
+4
New +$61 ﹤0.01% 4423

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Carson Wealth (CWM LLC)'s ELVN Position: Q1 2026 in Review

Carson Wealth (CWM LLC) increased its Enliven Therapeutics (ELVN) stake by 51% in Q1 2026, buying an estimated $1.33K and bringing the position to 142 shares worth $5.57K. The position accounts for ﹤0.01% of the portfolio, ranked #4984.

Carson Wealth (CWM LLC) first reported a position in ELVN in Q1 2024 and has held it in 9 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Carson Wealth (CWM LLC) held 142 shares of Enliven Therapeutics worth $5.57K as of Q1 2026.
  • Carson Wealth (CWM LLC) bought 48 Enliven Therapeutics shares in Q1 2026, an estimated $1.33K.
  • Enliven Therapeutics made up ﹤0.01% of Carson Wealth (CWM LLC)'s portfolio in Q1 2026, its #4984 holding.
  • Carson Wealth (CWM LLC) first reported a position in Enliven Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q1 2026, filed 14 May 2026.